tislelizumab - Robuta Search

https://www.mountsinai.org/clinical-trials/study-investigating-bgb-26808-alone-in-combination-with-tislelizumab-in-participants-with-advanced-solid-tumors A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With... a study https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1618898/full Frontiers | Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for... ObjectiveTo evaluate the efficacy and safety of Tislelizumab combined with Axitinib in the treatment of intermediate-high risk metastatic clear-cell renal ce... https://www.cancer.gov/about-cancer/treatment/drugs/tislelizumab-jsgr Tislelizumab-jsgr - NCI Tislelizumab-jsgr works by keeping cancer cells from suppressing the immune system. It binds to the protein PD-1 on the surface of immune cells called T cells,... tislelizumab jsgr nci https://www.biospace.com/beigene-announces-inclusion-in-the-china-national-reimbursement-drug-list-nrdl-of-tislelizumab-in-three-new-indications-brukinsa-zanubrutinib-in-one-new-indication-and-the-first-listing-for-pamiparib BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in... Dec 3, 2021 - BeiGene, a global science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for... https://elifesciences.org/reviewed-preprints/103559v2/figures Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in... gamma knife stereotactic radiotherapy https://www.esmo.org/oncology-news/ema-recommends-to-extend-the-indications-for-tislelizumab EMA Recommends to Extend the Indications for Tislelizumab New indication concerns a combination with etoposide and platinum chemotherapy for the first-line treatment of adult patients with extensive-stage SCLC ema recommends extend indications tislelizumab https://elifesciences.org/reviewed-preprints/103559v1/reviews Gamma Knife Stereotactic radiotherapy combined with tislelizumab as later-line therapy in... gamma knife stereotactic radiotherapy https://es.wikipedia.org/wiki/Tislelizumab Tislelizumab - Wikipedia, la enciclopedia libre tislelizumab wikipedia la enciclopedia libre https://www.nice.org.uk/guidance/indevelopment/gid-ta11100 Project information | Tislelizumab with chemotherapy for untreated recurrent or metastatic... Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] project information tislelizumab chemotherapy untreated recurrent https://www.business-standard.com/amp/content/press-releases-ani/glenmark-and-beigene-enter-into-an-agreement-for-marketing-and-distribution-of-tislelizumab-and-zanubrutinib-in-india-124052100411_1.html Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and... Mumbai (Maharashtra) [India], May 21: Glenmark Specialty S.A. (Glenmark), a subsidiary of Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1402490/full Frontiers | Tislelizumab plus chemotherapy in metastatic extramammary Paget disease after surgery:... Extramammary Paget disease (EMPD) is a rare epithelial adenocarcinoma in apocrine-gland rich skin, involving the vulva, the scrotum, and the penis. with dist... extramammary paget disease frontiers tislelizumab plus chemotherapy https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1172969/full Frontiers | Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the... Purpose: Pembrolizumab and tislelizumab have demonstrated significant clinical benefits in first-line treatment for advanced NSCLC. However, no head-to-head ... frontiers tislelizumab plus chemotherapy versus https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1521828/full Frontiers | SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved... SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) typically lacks target-driven gene alterations and are primarily resistant to cytotoxic drugs. ...